跳至主要内容
临床试验/ACTRN12614000496617
ACTRN12614000496617进行中(未招募)4 期

Study of audiometry, speech reception threshold, retinal vasculature, inflammatory marker and neurocognitive effects of aspirin in age-related hearing loss to determine the effects of daily low-dose aspirin 100mg versus placebo on hearing outcomes in the setting of in healthy older adults aged 70 years and over

Monash University0 个研究点目标入组 1,262 人开始时间: 2014年5月12日最近更新:
适应症

试验速览

阶段
4 期
状态
进行中(未招募)
入组人数
1,262

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Prevention
盲法
Blinded (masking used)

入排标准

年龄范围
70 Years 至 o limit(—)
性别
All

入选标准

  • Enrolments into the ASPREE parent study, aged 70 years and over who are able and willing to provide informed consent

排除标准

  • History of a diagnosed cardiovascular event, including AMI and stroke, atrial fibrillation, serious intercurrent illness likely to cause death within 5 years, cognitive impairment or dementia, disability, anaemia, a current or recurrent condition with a high risk of major bleeding, absolute contraindication or allergy to aspirin.
  • Specific exclusion criteria for participation in ASPREE-HEARING include the presence of bilateral Lyric or internal hearing aids or bilateral cochlear imnplants.

研究者

相似试验